Healthcare - Press Releases

YANTAI, Chine, 24 avril 2025 /PRNewswire/ -- En neurochirurgie, il est essentiel, mais difficile, d'obtenir des informations en temps rel sur le dbit sanguin crbral. L'imagerie conventionnelle par fluorescence du vert d'indocyanine (ICG) repose sur des agents de contraste et offre une rptabilit limite. Aujourd'hui, les camras de thermographie infrarouge offrent une alternative d'imagerie diagnostique sans contact, sans contraste, sans rayonnement et non invasive, ce qui permet une surveillance continue pour amliorer la prcision chirurgicale et la scurit des patients.

SHANGHAI and HONG KONG, April 23, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that it will release the latest clinical data of the CD73 small molecule inhibitor ATG-037 and the mTORC1/2 small molecule inhibitor ATG-008 in Poster Presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30th to June 3rd in Chicago, IL, the United States.

CHENGDU, China, April 24, 2025 /PRNewswire/ -- SichuanKelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 30 to June 3. Results include data from its TROP2 antibody-drug conjugate (ADC)sacituzumab tirumotecan(sac-TMT), anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031). The abstracts for these studies will be published on the ASCO's official website on May 22, 2025, local time.

Solid performance with higher sales and strong cash flow

Solid performance with higher sales and strong cash flow

SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com.

GOTHENBURG, Sweden, April 24, 2025 /PRNewswire/ --

Strong product sales and key progress in pipeline catalysts

Strong product sales and key progress in pipeline catalysts

- Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA models featured in two peer-reviewed articles -

YANTAI, China, 24. April 2025 /PRNewswire/ -- In der Neurochirurgie mit hohem Einsatzist die Gewinnung von Echtzeit-Einblicken in den zerebralen Blutfluss lebenswichtig, aber auch eine Herausforderung. Die herkmmliche Indocyaningrn (ICG)-Fluoreszenzbildgebung ist auf Kontrastmittel angewiesen und bietet nur eine begrenzte Wiederholbarkeit. Jetzt versprechen Infrarot-Thermografiekameras eine berhrungslose, kontrastfreie, strahlungsfreie und nicht-invasive Alternative zur diagnostischen Bildgebung, die eine kontinuierliche berwachung ermglicht und die chirurgische Przision und Patientensicherheit erhht.

-Intellisense AFib Technology Able to Detect Possible Atrial Fibrillation with Every Measurement; May 17 Marks World Hypertension Day during May Measurement Month -

-Intellisense AFib Technology Able to Detect Possible Atrial Fibrillation with Every Measurement; May 17 Marks World Hypertension Day during May Measurement Month -

GOSSELIES, Belgium and NANTES, France, April 24, 2025 /PRNewswire/ -- AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the formation of its Scientific Advisory Board (SAB), which is comprised of industry experts in autoimmune and inflammatory disease drug development. The SAB will work closely with the AbolerIS team to advance its lead program, ABO21009, a humanized anti-CD45RC monoclonal antibody, through Phase 1 for rheumatoid arthritis (RA). Pending clinical proof-of-concept in RA, the Company intends to broaden its development into other autoimmune diseases. Durable, long-term remission remains elusive in many autoimmune diseases such as RA. The SAB will also assist the AbolerIS management with the planned development of additional indications for ABO21009 and the expansion and subsequent development of the Company's portfolio.

LOS ALTOS, Calif., April 24, 2025 /PRNewswire/ -- XYRA LLC, a private biopharmaceutical company, is committed to developing innovative therapies for cardiac rhythm disorders with high unmet need. With widespread use of FDA approved wearable Atrial Fibrillation (AF) monitoring devices in detecting as well as monitoring arrhythmias, it is now possible to identify subjects with long episodes of AF (LEAF) and symptoms who are at high risk of complications including stroke, heart failure and progression to permanent AF.

Revenue and Profit Surge, Driven by "AI + Health Care" Value Empowerment

AI-powered, on-demand access to clinical content enhances HCP interactions and drives measurable commercial impact for pharmaceutical companies.

Broadstreet Global is proud to support the Donovan & Bank Foundation's mission to help elite Special Operators navigate life after service through mental wellness and reintegration programs. As the Foundation hosted its immersive AREA B experience this April in North Carolina, Broadstreet's contributions continue to help expand and sustain this critical work.

LISBONNE, Portugal, 15 avril 2025 /PRNewswire/ -- La ngligence est l'une des menaces les plus rpandues et les plus ngliges pour le bien-tre d'un enfant. Contrairement l'abandon, la ngligence passe souvent inaperue, laissant les enfants pigs dans des cycles de souffrance motionnelle chronique, de confiance brise et de difficults de dveloppement long terme.

HAZLETON, Pa., April 16, 2025 /PRNewswire/ -- After more than 30 years as a trusted name in topical pain relief,Stopainis experiencing a remarkable resurgence. With millions of loyal users, the brand has not only stood the test of time but has also accelerated ahead of the competition. In 2024, Stopain grew over three times faster than the category at the largest retailer in the U.S., proving that its powerful formula, exceptional value, and unwavering availability are resonating with consumers more than ever.

SEATTLE, April 15, 2025 /PRNewswire/ -- Children's Miracle Network Hospitals (CMN Hospitals) announced GoWest Credit Union Association and member credit unions received the 2025 Event of the Year for its annual MAXX CU4Kids Benefit Auction. This national recognition celebrates the legacy and impact of GoWest's signature fundraising event and the generosity of credit unions throughout the region.

Headline Summary: Developed by founder Bracha L. Banayan, NP, The DROP Method is the first patient-centered framework that empowers GLP-1 users to take control of their health, behaviors, and long-term weight loss success.

Animal rights organization thanks Trump Administration for ending decades of government-sanctioned animal abuse

TRENTON, N.J., April 15, 2025 /PRNewswire/ -- BioNJ is proud to present its 15th Annual BioPartnering Conference on Tuesday, May 13, at the Liberty Science Center in Jersey City. We're especially excited to welcome BioNJ Member CoreWeave as the newest addition to our esteemed group of Marquis Conference Partners, joining J.P. Morgan and Morgan Lewis.

'It's about putting rigorous, evidence-aligned research into the hands of practitioners'